TTC16 Activators
Tetratricopeptide repeat domain 16 (TTC16) activators encompass a variety of chemical compounds that exert their effects through distinct biochemical pathways, ultimately enhancing the function and activity of TTC16 within cells. Agents that elevate intracellular cyclic AMP (cAMP) levels, such as those that directly stimulate adenylate cyclase or inhibit the degradation of cAMP, enhance protein kinase A activity. This kinase, in turn, can phosphorylate substrate proteins, potentially including TTC16, therefore amplifying its activity. Similarly, catecholamine analogs that engage with beta-adrenergic receptors also raise cAMP levels, which may lead to an upregulation of TTC16 activity via cAMP-dependent signaling pathways. The enhancement of cAMP and cGMP levels through selective inhibition of their respective phosphodiesterases also indirectly activates TTC16 by potentiating the signaling cascades they govern.
Additional mechanisms of TTC16 activation involve the modulation of intracellular calcium levels and the perturbation of specific kinase pathways. Calcium ionophores that increase cytosolic calcium concentrations activate calcium/calmodulin-dependent protein kinases, which may then contribute to the activation of TTC16 as part of calcium-mediated signaling. Similarly, inhibitors of phospholipase C and PI3K/Akt pathways, as well as those targeting p38 MAP kinase, may initiate compensatory responses within the cell, leading to the activation of alternative signaling routes that converge on TTC16 activation. The alteration of these pathways can trigger a re-balancing of cellular signaling networks, potentially enhancing the functional activity of TTC16. Furthermore, the stress-activated protein kinase pathway, which can be modulated by specific protein synthesis inhibitors, may also play a role in upregulating TTC16 in response to cellular stress signals. Finally, the inhibition of Ca2+/calmodulin-dependent protein kinase and protein kinase C can lead to the activation of TTC16 through feedback mechanisms within their respective pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
This diterpene acts by directly stimulating adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels within the cell. Elevated cAMP can enhance the protein kinase A (PKA) pathway, which may upregulate the functional activity of TTC16 through phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
A synthetic catecholamine and beta-adrenergic agonist that triggers the beta-adrenergic receptor leading to adenylate cyclase activation and a subsequent rise in cAMP levels. This cascade potentially upregulates TTC16 activity through cAMP-dependent signaling mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
A nonspecific inhibitor of phosphodiesterases, it prevents the breakdown of cAMP and cGMP, thus potentiating their signaling effects. The increased cAMP can enhance the PKA pathway, potentially increasing the activation of TTC16. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Acts as a protein synthesis inhibitor and can activate stress-activated protein kinases such as JNK. This stress response may upregulate TTC16 function as part of the cellular response to stress. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
A diester of phorbol and a potent activator of protein kinase C (PKC). Activation of PKC has been implicated in the modulation of numerous proteins and may lead to the activation of TTC16 through PKC-dependent signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
An ionophore that increases intracellular calcium levels, which could activate calcium-dependent pathways including calmodulin-dependent kinases. These kinases may enhance TTC16 activation as part of calcium signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore that elevates intracellular calcium levels, potentially stimulating calcium/calmodulin-dependent protein kinases which could lead to the activation of TTC16. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
A selective inhibitor of phosphodiesterase 5 (PDE5), which leads to increased cGMP levels in cells. This elevation may activate cGMP-dependent protein kinases, which could indirectly upregulate TTC16 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of the PI3K/Akt pathway, which can lead to alterations in downstream signaling pathways. Inhibition of PI3K can result in compensatory mechanisms that might activate TTC16 through feedback regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A specific inhibitor of p38 MAP kinase, which could release the inhibition on alternative signaling pathways, potentially leading to the activation of TTC16 through compensatory cellular responses. | ||||||